Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Squamous Cell | 35 | 2023 | 1096 | 5.990 |
Why?
|
Head and Neck Neoplasms | 39 | 2024 | 1063 | 5.440 |
Why?
|
Oropharyngeal Neoplasms | 16 | 2024 | 132 | 4.080 |
Why?
|
Mouth Neoplasms | 12 | 2023 | 198 | 3.390 |
Why?
|
Papillomavirus Infections | 17 | 2024 | 261 | 3.250 |
Why?
|
DNA, Neoplasm | 10 | 2020 | 268 | 2.310 |
Why?
|
Thyroid Neoplasms | 12 | 2024 | 424 | 2.280 |
Why?
|
Mutation | 27 | 2024 | 4137 | 1.400 |
Why?
|
Carcinoma | 8 | 2022 | 443 | 1.330 |
Why?
|
Receptor, Notch1 | 9 | 2020 | 94 | 1.260 |
Why?
|
Papillomaviridae | 9 | 2022 | 156 | 1.230 |
Why?
|
Tongue Neoplasms | 7 | 2023 | 52 | 1.220 |
Why?
|
Laryngectomy | 8 | 2017 | 26 | 1.110 |
Why?
|
Biomarkers, Tumor | 12 | 2022 | 1547 | 1.090 |
Why?
|
Neck Dissection | 5 | 2017 | 67 | 1.060 |
Why?
|
Exome | 5 | 2017 | 127 | 0.990 |
Why?
|
Humans | 123 | 2024 | 89157 | 0.940 |
Why?
|
Tonsillar Neoplasms | 3 | 2019 | 6 | 0.920 |
Why?
|
Tumor Suppressor Protein p53 | 8 | 2020 | 414 | 0.910 |
Why?
|
Neoplasms, Second Primary | 2 | 2016 | 260 | 0.890 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 319 | 0.870 |
Why?
|
Coronavirus Infections | 4 | 2020 | 304 | 0.860 |
Why?
|
Disease Transmission, Infectious | 2 | 2020 | 58 | 0.850 |
Why?
|
Laryngeal Neoplasms | 5 | 2017 | 89 | 0.840 |
Why?
|
Alphapapillomavirus | 4 | 2021 | 45 | 0.830 |
Why?
|
Saliva | 3 | 2021 | 123 | 0.830 |
Why?
|
Salivary Gland Neoplasms | 3 | 2022 | 67 | 0.830 |
Why?
|
Middle Aged | 55 | 2024 | 25910 | 0.760 |
Why?
|
Betacoronavirus | 3 | 2020 | 261 | 0.750 |
Why?
|
Male | 68 | 2024 | 42309 | 0.730 |
Why?
|
Carcinoma, Adenoid Cystic | 2 | 2022 | 31 | 0.730 |
Why?
|
Pandemics | 4 | 2020 | 771 | 0.720 |
Why?
|
Carcinoma, Papillary | 4 | 2017 | 159 | 0.720 |
Why?
|
Neoplasm Recurrence, Local | 11 | 2024 | 1363 | 0.720 |
Why?
|
Tracheotomy | 1 | 2020 | 18 | 0.710 |
Why?
|
Neoplasm Staging | 14 | 2022 | 2002 | 0.700 |
Why?
|
Palatine Tonsil | 1 | 2019 | 30 | 0.680 |
Why?
|
Neoplasm Invasiveness | 9 | 2021 | 576 | 0.670 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 4 | 2024 | 164 | 0.660 |
Why?
|
Nasopharyngeal Neoplasms | 2 | 2016 | 47 | 0.640 |
Why?
|
Female | 66 | 2024 | 46078 | 0.640 |
Why?
|
Pathology, Molecular | 1 | 2018 | 34 | 0.620 |
Why?
|
Dental Alloys | 1 | 2018 | 5 | 0.620 |
Why?
|
Orthodontic Appliances | 1 | 2018 | 7 | 0.620 |
Why?
|
Respiratory Insufficiency | 1 | 2020 | 162 | 0.620 |
Why?
|
Thyroidectomy | 7 | 2022 | 171 | 0.590 |
Why?
|
Prognosis | 17 | 2022 | 3776 | 0.590 |
Why?
|
Life Style | 1 | 2018 | 172 | 0.570 |
Why?
|
Liquid Biopsy | 4 | 2023 | 33 | 0.560 |
Why?
|
Neoplasm Proteins | 1 | 2020 | 540 | 0.540 |
Why?
|
NFI Transcription Factors | 1 | 2016 | 7 | 0.540 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2016 | 133 | 0.540 |
Why?
|
Translocation, Genetic | 2 | 2016 | 266 | 0.530 |
Why?
|
Practice Guidelines as Topic | 3 | 2017 | 1043 | 0.520 |
Why?
|
Incidence | 8 | 2023 | 1593 | 0.520 |
Why?
|
Disability Evaluation | 1 | 2016 | 140 | 0.520 |
Why?
|
Aged | 36 | 2024 | 19119 | 0.510 |
Why?
|
Genetic Predisposition to Disease | 4 | 2015 | 2338 | 0.500 |
Why?
|
Genes, Tumor Suppressor | 3 | 2014 | 160 | 0.500 |
Why?
|
Positron-Emission Tomography | 3 | 2016 | 336 | 0.490 |
Why?
|
Adult | 40 | 2024 | 26542 | 0.490 |
Why?
|
Neck | 4 | 2015 | 103 | 0.490 |
Why?
|
Adenocarcinoma | 3 | 2024 | 1194 | 0.460 |
Why?
|
Cell Cycle Proteins | 2 | 2018 | 401 | 0.450 |
Why?
|
Postoperative Complications | 8 | 2016 | 2278 | 0.440 |
Why?
|
Thyroid Carcinoma, Anaplastic | 2 | 2024 | 15 | 0.440 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 154 | 0.440 |
Why?
|
Salvage Therapy | 3 | 2015 | 235 | 0.440 |
Why?
|
Carcinoma, Medullary | 1 | 2012 | 10 | 0.430 |
Why?
|
Retrospective Studies | 20 | 2022 | 9022 | 0.430 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2012 | 23 | 0.430 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2023 | 71 | 0.410 |
Why?
|
Lymph Nodes | 5 | 2017 | 548 | 0.410 |
Why?
|
Barrett Esophagus | 1 | 2012 | 93 | 0.400 |
Why?
|
F-Box Proteins | 1 | 2011 | 11 | 0.390 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2011 | 20 | 0.390 |
Why?
|
Ubiquitin-Protein Ligases | 3 | 2011 | 170 | 0.390 |
Why?
|
Cell-Free Nucleic Acids | 2 | 2023 | 83 | 0.390 |
Why?
|
Clostridium | 4 | 2005 | 23 | 0.380 |
Why?
|
Cohort Studies | 10 | 2023 | 2864 | 0.370 |
Why?
|
Monitoring, Intraoperative | 4 | 2018 | 110 | 0.370 |
Why?
|
United States | 12 | 2023 | 6965 | 0.360 |
Why?
|
Tonsillectomy | 3 | 2023 | 30 | 0.360 |
Why?
|
Recurrent Laryngeal Nerve Injuries | 2 | 2022 | 17 | 0.360 |
Why?
|
Esophageal Neoplasms | 2 | 2012 | 332 | 0.350 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 2553 | 0.340 |
Why?
|
Aged, 80 and over | 18 | 2023 | 6794 | 0.330 |
Why?
|
Radiotherapy, Intensity-Modulated | 3 | 2016 | 176 | 0.330 |
Why?
|
ras Proteins | 2 | 2020 | 130 | 0.330 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2020 | 481 | 0.310 |
Why?
|
SEER Program | 3 | 2023 | 197 | 0.310 |
Why?
|
Sex Factors | 5 | 2018 | 1063 | 0.310 |
Why?
|
Carcinoma in Situ | 1 | 2008 | 53 | 0.310 |
Why?
|
Parathyroid Hormone | 3 | 2018 | 217 | 0.300 |
Why?
|
Age Factors | 5 | 2018 | 1867 | 0.300 |
Why?
|
Risk Factors | 7 | 2023 | 5483 | 0.290 |
Why?
|
Pharyngectomy | 3 | 2016 | 8 | 0.290 |
Why?
|
Hyperparathyroidism, Primary | 2 | 2018 | 42 | 0.290 |
Why?
|
Neoplasms, Experimental | 3 | 2005 | 269 | 0.280 |
Why?
|
Sequence Analysis, DNA | 4 | 2016 | 866 | 0.280 |
Why?
|
Oncogenes | 2 | 2020 | 92 | 0.280 |
Why?
|
Goiter | 2 | 2018 | 43 | 0.280 |
Why?
|
Receptors, Notch | 3 | 2022 | 123 | 0.270 |
Why?
|
Radiotherapy Dosage | 4 | 2020 | 470 | 0.270 |
Why?
|
Chemoradiotherapy | 5 | 2022 | 309 | 0.270 |
Why?
|
Patient Selection | 3 | 2020 | 684 | 0.270 |
Why?
|
Thyroid Gland | 3 | 2022 | 280 | 0.270 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2020 | 112 | 0.270 |
Why?
|
Repressor Proteins | 3 | 2015 | 423 | 0.260 |
Why?
|
Disease-Free Survival | 4 | 2020 | 1214 | 0.260 |
Why?
|
Thyroid Nodule | 2 | 2016 | 58 | 0.250 |
Why?
|
Gene Expression Profiling | 5 | 2020 | 1429 | 0.250 |
Why?
|
ErbB Receptors | 2 | 2020 | 500 | 0.240 |
Why?
|
DNA Mutational Analysis | 5 | 2016 | 529 | 0.240 |
Why?
|
Tumor Microenvironment | 3 | 2024 | 461 | 0.240 |
Why?
|
Risk Assessment | 7 | 2018 | 2302 | 0.230 |
Why?
|
Databases, Factual | 3 | 2018 | 851 | 0.230 |
Why?
|
Hypothermia | 1 | 2003 | 26 | 0.220 |
Why?
|
Quinolones | 1 | 2024 | 60 | 0.220 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2020 | 1265 | 0.220 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2022 | 146 | 0.220 |
Why?
|
Ganglioneuroblastoma | 1 | 2023 | 4 | 0.220 |
Why?
|
Young Adult | 8 | 2022 | 6294 | 0.220 |
Why?
|
DNA, Viral | 2 | 2022 | 262 | 0.220 |
Why?
|
Brain Neoplasms | 3 | 2015 | 781 | 0.220 |
Why?
|
Extracellular Vesicles | 1 | 2023 | 42 | 0.210 |
Why?
|
Osteoradionecrosis | 1 | 2022 | 18 | 0.210 |
Why?
|
Head | 1 | 2003 | 135 | 0.210 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2015 | 447 | 0.210 |
Why?
|
Re-Irradiation | 1 | 2022 | 15 | 0.210 |
Why?
|
Oral Health | 2 | 2022 | 10 | 0.210 |
Why?
|
Decision Making | 2 | 2020 | 665 | 0.210 |
Why?
|
Caenorhabditis elegans Proteins | 1 | 2023 | 113 | 0.200 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2024 | 340 | 0.200 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2023 | 248 | 0.200 |
Why?
|
Intraoperative Complications | 1 | 2003 | 188 | 0.200 |
Why?
|
Gastric Bypass | 1 | 2023 | 110 | 0.200 |
Why?
|
Smoking | 3 | 2020 | 621 | 0.200 |
Why?
|
Lymphatic Metastasis | 5 | 2021 | 502 | 0.200 |
Why?
|
Neoplasm Metastasis | 4 | 2020 | 1108 | 0.190 |
Why?
|
Cloud Computing | 1 | 2021 | 11 | 0.190 |
Why?
|
DNA Helicases | 2 | 2012 | 84 | 0.190 |
Why?
|
DNA Methylation | 3 | 2015 | 657 | 0.190 |
Why?
|
Transcriptome | 3 | 2021 | 628 | 0.190 |
Why?
|
Survival Analysis | 5 | 2018 | 1534 | 0.190 |
Why?
|
Societies, Medical | 4 | 2018 | 570 | 0.190 |
Why?
|
RNA, Messenger | 4 | 2016 | 2011 | 0.190 |
Why?
|
Drug Monitoring | 1 | 2022 | 119 | 0.190 |
Why?
|
Neoadjuvant Therapy | 1 | 2024 | 374 | 0.190 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2021 | 17 | 0.190 |
Why?
|
Carcinoma, Papillary, Follicular | 1 | 2020 | 14 | 0.190 |
Why?
|
Parathyroidectomy | 2 | 2018 | 77 | 0.190 |
Why?
|
Surveys and Questionnaires | 2 | 2020 | 2614 | 0.190 |
Why?
|
Follow-Up Studies | 8 | 2020 | 3660 | 0.190 |
Why?
|
Carcinoma, Basal Cell | 1 | 2021 | 61 | 0.180 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2022 | 170 | 0.180 |
Why?
|
Nuclear Proteins | 4 | 2012 | 726 | 0.180 |
Why?
|
Larynx, Artificial | 2 | 2011 | 2 | 0.180 |
Why?
|
Bariatric Surgery | 1 | 2023 | 195 | 0.180 |
Why?
|
User-Computer Interface | 1 | 2021 | 187 | 0.180 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2020 | 14 | 0.180 |
Why?
|
Oncogene Protein v-akt | 1 | 2020 | 21 | 0.180 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2015 | 296 | 0.180 |
Why?
|
Early Detection of Cancer | 2 | 2021 | 415 | 0.180 |
Why?
|
Bacteria | 2 | 2023 | 472 | 0.180 |
Why?
|
Obesity, Morbid | 1 | 2023 | 233 | 0.180 |
Why?
|
Serine Endopeptidases | 1 | 2020 | 146 | 0.170 |
Why?
|
Genome, Mitochondrial | 1 | 2019 | 27 | 0.170 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2023 | 216 | 0.170 |
Why?
|
Cyclin D1 | 1 | 2020 | 84 | 0.170 |
Why?
|
Checklist | 1 | 2020 | 61 | 0.170 |
Why?
|
Surgery Department, Hospital | 1 | 2020 | 44 | 0.170 |
Why?
|
Predictive Value of Tests | 2 | 2016 | 1720 | 0.170 |
Why?
|
Retinoblastoma Protein | 1 | 2020 | 67 | 0.170 |
Why?
|
Immunotherapy, Adoptive | 1 | 2021 | 189 | 0.170 |
Why?
|
Brain Stem Neoplasms | 1 | 2019 | 17 | 0.170 |
Why?
|
Health Resources | 1 | 2020 | 81 | 0.170 |
Why?
|
Radiation Dosage | 1 | 2020 | 226 | 0.170 |
Why?
|
Human papillomavirus 16 | 2 | 2016 | 38 | 0.170 |
Why?
|
DNA, Mitochondrial | 1 | 2019 | 187 | 0.160 |
Why?
|
Neoplasms | 5 | 2023 | 3037 | 0.160 |
Why?
|
Point Mutation | 1 | 2019 | 245 | 0.160 |
Why?
|
Elective Surgical Procedures | 1 | 2020 | 126 | 0.160 |
Why?
|
Infection Control | 1 | 2020 | 120 | 0.160 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2021 | 394 | 0.160 |
Why?
|
Treatment Outcome | 7 | 2022 | 8217 | 0.160 |
Why?
|
Glossectomy | 2 | 2016 | 4 | 0.160 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 187 | 0.160 |
Why?
|
Consensus | 2 | 2018 | 356 | 0.160 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2022 | 397 | 0.150 |
Why?
|
beta Catenin | 1 | 2020 | 266 | 0.150 |
Why?
|
Computational Biology | 1 | 2021 | 542 | 0.150 |
Why?
|
APOBEC Deaminases | 1 | 2017 | 5 | 0.150 |
Why?
|
Incidental Findings | 1 | 2018 | 98 | 0.150 |
Why?
|
Academic Medical Centers | 3 | 2020 | 385 | 0.150 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2024 | 267 | 0.150 |
Why?
|
Carboplatin | 3 | 2024 | 304 | 0.150 |
Why?
|
Reoperation | 3 | 2016 | 598 | 0.150 |
Why?
|
Confidence Intervals | 1 | 2018 | 225 | 0.150 |
Why?
|
Glottis | 1 | 2017 | 11 | 0.150 |
Why?
|
Metals | 1 | 2018 | 93 | 0.150 |
Why?
|
Respiration, Artificial | 1 | 2020 | 352 | 0.150 |
Why?
|
Combined Modality Therapy | 3 | 2016 | 1710 | 0.150 |
Why?
|
Hypocalcemia | 2 | 2014 | 43 | 0.140 |
Why?
|
Lung Neoplasms | 3 | 2022 | 2347 | 0.140 |
Why?
|
Tertiary Care Centers | 2 | 2020 | 106 | 0.140 |
Why?
|
Cell Line, Tumor | 6 | 2024 | 2553 | 0.140 |
Why?
|
Genomics | 3 | 2024 | 761 | 0.140 |
Why?
|
Survival Rate | 3 | 2020 | 1890 | 0.140 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 170 | 0.140 |
Why?
|
Paclitaxel | 3 | 2024 | 479 | 0.140 |
Why?
|
Adolescent | 7 | 2022 | 9243 | 0.140 |
Why?
|
Arabinofuranosyluracil | 2 | 2007 | 6 | 0.140 |
Why?
|
Sclerotherapy | 1 | 2016 | 16 | 0.140 |
Why?
|
Thymidine Kinase | 2 | 2007 | 30 | 0.140 |
Why?
|
Vascular Malformations | 1 | 2016 | 19 | 0.140 |
Why?
|
Carcinoma, Mucoepidermoid | 1 | 2016 | 17 | 0.140 |
Why?
|
Gene Silencing | 2 | 2014 | 178 | 0.140 |
Why?
|
Fibromatosis, Aggressive | 1 | 2016 | 11 | 0.140 |
Why?
|
Exons | 3 | 2015 | 451 | 0.140 |
Why?
|
Endoscopy | 2 | 2011 | 348 | 0.130 |
Why?
|
Bleomycin | 1 | 2016 | 102 | 0.130 |
Why?
|
Tomography, X-Ray Computed | 4 | 2016 | 2658 | 0.130 |
Why?
|
Prophylactic Surgical Procedures | 1 | 2016 | 7 | 0.130 |
Why?
|
Oncogene Proteins, Viral | 1 | 2015 | 34 | 0.130 |
Why?
|
Intubation, Gastrointestinal | 1 | 2016 | 31 | 0.130 |
Why?
|
Time Factors | 5 | 2018 | 5331 | 0.130 |
Why?
|
Receptor, Notch2 | 2 | 2012 | 6 | 0.130 |
Why?
|
Nerve Tissue Proteins | 3 | 2009 | 511 | 0.130 |
Why?
|
Skin Neoplasms | 1 | 2021 | 579 | 0.130 |
Why?
|
Proton Therapy | 1 | 2015 | 32 | 0.130 |
Why?
|
DNA-Binding Proteins | 2 | 2012 | 1241 | 0.130 |
Why?
|
Calcium | 2 | 2018 | 1174 | 0.130 |
Why?
|
Epigenesis, Genetic | 1 | 2020 | 507 | 0.130 |
Why?
|
North America | 2 | 2013 | 184 | 0.130 |
Why?
|
Referral and Consultation | 1 | 2018 | 341 | 0.130 |
Why?
|
China | 2 | 2014 | 233 | 0.130 |
Why?
|
Esophagectomy | 1 | 2016 | 92 | 0.130 |
Why?
|
Lymph Node Excision | 1 | 2017 | 220 | 0.130 |
Why?
|
Guideline Adherence | 1 | 2017 | 229 | 0.130 |
Why?
|
Biopsy | 1 | 2019 | 1182 | 0.130 |
Why?
|
Spores, Bacterial | 2 | 2005 | 18 | 0.130 |
Why?
|
Spinal Cord Neoplasms | 1 | 2015 | 48 | 0.130 |
Why?
|
Signal Transduction | 5 | 2022 | 3376 | 0.120 |
Why?
|
Carbolines | 1 | 2015 | 8 | 0.120 |
Why?
|
Gene Rearrangement | 1 | 2016 | 172 | 0.120 |
Why?
|
Mandible | 1 | 2016 | 120 | 0.120 |
Why?
|
Phosphodiesterase 5 Inhibitors | 1 | 2015 | 10 | 0.120 |
Why?
|
Alcohol Drinking | 1 | 2018 | 273 | 0.120 |
Why?
|
Leukoplakia, Oral | 1 | 2014 | 12 | 0.120 |
Why?
|
Primary Health Care | 1 | 2018 | 351 | 0.120 |
Why?
|
Algorithms | 4 | 2016 | 1875 | 0.120 |
Why?
|
Decision Support Techniques | 1 | 2016 | 167 | 0.120 |
Why?
|
Mouth Mucosa | 1 | 2014 | 67 | 0.120 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2014 | 15 | 0.120 |
Why?
|
Gene Dosage | 2 | 2013 | 208 | 0.120 |
Why?
|
Pharyngeal Neoplasms | 1 | 2014 | 15 | 0.120 |
Why?
|
Zenker Diverticulum | 1 | 2014 | 9 | 0.120 |
Why?
|
Deglutition Disorders | 1 | 2016 | 119 | 0.120 |
Why?
|
Immunotherapy | 1 | 2020 | 669 | 0.120 |
Why?
|
Sex Distribution | 1 | 2014 | 171 | 0.120 |
Why?
|
Immunity, Cellular | 1 | 2015 | 178 | 0.120 |
Why?
|
Bacterial Toxins | 2 | 2005 | 114 | 0.120 |
Why?
|
Age Distribution | 1 | 2014 | 200 | 0.120 |
Why?
|
Antibodies, Viral | 1 | 2015 | 309 | 0.120 |
Why?
|
Hashimoto Disease | 1 | 2013 | 11 | 0.120 |
Why?
|
Promoter Regions, Genetic | 2 | 2014 | 956 | 0.110 |
Why?
|
Carcinogenesis | 1 | 2016 | 211 | 0.110 |
Why?
|
Clinical Decision-Making | 1 | 2016 | 280 | 0.110 |
Why?
|
Metagenome | 1 | 2014 | 104 | 0.110 |
Why?
|
Enteral Nutrition | 3 | 2020 | 102 | 0.110 |
Why?
|
Genes, Neoplasm | 1 | 2013 | 37 | 0.110 |
Why?
|
Animals | 14 | 2023 | 27330 | 0.110 |
Why?
|
Radiography | 1 | 2015 | 809 | 0.110 |
Why?
|
Ependymoma | 1 | 2013 | 18 | 0.110 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1114 | 0.110 |
Why?
|
Mutation, Missense | 2 | 2011 | 277 | 0.110 |
Why?
|
Case-Control Studies | 4 | 2023 | 1855 | 0.110 |
Why?
|
Papanicolaou Test | 1 | 2013 | 39 | 0.110 |
Why?
|
Radiotherapy, High-Energy | 1 | 2012 | 49 | 0.110 |
Why?
|
Receptor, Notch3 | 1 | 2012 | 4 | 0.110 |
Why?
|
Astrocytoma | 1 | 2013 | 82 | 0.110 |
Why?
|
Vaginal Smears | 1 | 2013 | 70 | 0.110 |
Why?
|
Intensive Care Units | 1 | 2016 | 396 | 0.110 |
Why?
|
Adoptive Transfer | 2 | 2021 | 169 | 0.100 |
Why?
|
Patient Readmission | 1 | 2016 | 352 | 0.100 |
Why?
|
Vocal Cords | 2 | 2011 | 27 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 64 | 0.100 |
Why?
|
Central Nervous System Neoplasms | 1 | 2013 | 85 | 0.100 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2012 | 55 | 0.100 |
Why?
|
F-Box-WD Repeat-Containing Protein 7 | 1 | 2011 | 4 | 0.100 |
Why?
|
Radiopharmaceuticals | 2 | 2016 | 193 | 0.100 |
Why?
|
Geography | 1 | 2012 | 227 | 0.100 |
Why?
|
INDEL Mutation | 1 | 2011 | 31 | 0.100 |
Why?
|
Oligodendroglioma | 1 | 2011 | 45 | 0.100 |
Why?
|
Codon, Nonsense | 1 | 2011 | 44 | 0.100 |
Why?
|
Proportional Hazards Models | 3 | 2022 | 848 | 0.100 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2012 | 63 | 0.100 |
Why?
|
Genes, p53 | 1 | 2011 | 109 | 0.090 |
Why?
|
Child | 6 | 2022 | 7154 | 0.090 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2011 | 75 | 0.090 |
Why?
|
Glioblastoma | 1 | 2013 | 265 | 0.090 |
Why?
|
Neurons | 3 | 2009 | 1580 | 0.090 |
Why?
|
Mice | 10 | 2021 | 11743 | 0.090 |
Why?
|
Mice, Inbred BALB C | 4 | 2005 | 1088 | 0.090 |
Why?
|
Models, Biological | 2 | 2015 | 1764 | 0.090 |
Why?
|
Lipomatosis | 1 | 2010 | 9 | 0.090 |
Why?
|
Endometrial Neoplasms | 1 | 2013 | 205 | 0.090 |
Why?
|
Cisplatin | 2 | 2022 | 617 | 0.090 |
Why?
|
Lipoma | 1 | 2010 | 27 | 0.090 |
Why?
|
MPTP Poisoning | 1 | 2009 | 3 | 0.090 |
Why?
|
Glioma | 1 | 2012 | 293 | 0.090 |
Why?
|
Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2009 | 27 | 0.090 |
Why?
|
Artificial Intelligence | 2 | 2023 | 322 | 0.090 |
Why?
|
DNA | 1 | 2015 | 1307 | 0.080 |
Why?
|
Minimally Invasive Surgical Procedures | 1 | 2011 | 251 | 0.080 |
Why?
|
Intestinal Neoplasms | 1 | 2010 | 64 | 0.080 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2011 | 695 | 0.080 |
Why?
|
Lung | 1 | 2015 | 1258 | 0.080 |
Why?
|
Safety Management | 2 | 2020 | 56 | 0.080 |
Why?
|
Biomarkers | 2 | 2023 | 1763 | 0.080 |
Why?
|
Speech, Alaryngeal | 1 | 2008 | 3 | 0.080 |
Why?
|
Neuroprotective Agents | 1 | 2009 | 100 | 0.080 |
Why?
|
Induction Chemotherapy | 2 | 2022 | 151 | 0.080 |
Why?
|
Biopsy, Fine-Needle | 3 | 2016 | 106 | 0.080 |
Why?
|
Base Sequence | 1 | 2012 | 2327 | 0.080 |
Why?
|
Voice Quality | 1 | 2008 | 13 | 0.080 |
Why?
|
Multivariate Analysis | 3 | 2016 | 988 | 0.080 |
Why?
|
Robotics | 1 | 2011 | 269 | 0.080 |
Why?
|
Orbital Neoplasms | 1 | 2008 | 17 | 0.080 |
Why?
|
Solitary Fibrous Tumors | 1 | 2008 | 5 | 0.080 |
Why?
|
Prospective Studies | 4 | 2022 | 4281 | 0.080 |
Why?
|
Intestine, Small | 1 | 2010 | 299 | 0.080 |
Why?
|
Microsurgery | 1 | 2008 | 88 | 0.080 |
Why?
|
Oral Fistula | 1 | 2007 | 2 | 0.070 |
Why?
|
Cutaneous Fistula | 1 | 2007 | 11 | 0.070 |
Why?
|
Fibrin Tissue Adhesive | 1 | 2007 | 15 | 0.070 |
Why?
|
Recurrence | 3 | 2018 | 1142 | 0.070 |
Why?
|
Laryngoscopy | 2 | 2022 | 47 | 0.070 |
Why?
|
Tissue Adhesives | 1 | 2007 | 23 | 0.070 |
Why?
|
Contrast Media | 1 | 2012 | 1090 | 0.070 |
Why?
|
Muscles | 1 | 2007 | 193 | 0.070 |
Why?
|
Longevity | 2 | 2023 | 58 | 0.070 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2007 | 73 | 0.070 |
Why?
|
Rabbits | 2 | 2005 | 638 | 0.070 |
Why?
|
Laser Therapy | 1 | 2008 | 149 | 0.070 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2005 | 277 | 0.070 |
Why?
|
Child, Preschool | 3 | 2023 | 3721 | 0.070 |
Why?
|
Risk | 2 | 2020 | 657 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2013 | 763 | 0.070 |
Why?
|
Bone and Bones | 1 | 2007 | 269 | 0.070 |
Why?
|
Bacterial Infections | 1 | 2007 | 184 | 0.070 |
Why?
|
Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) | 1 | 2005 | 5 | 0.060 |
Why?
|
S-Nitrosothiols | 1 | 2005 | 5 | 0.060 |
Why?
|
Tissue Distribution | 2 | 2022 | 293 | 0.060 |
Why?
|
Huntington Disease | 1 | 2005 | 38 | 0.060 |
Why?
|
Bacteriolysis | 1 | 2004 | 1 | 0.060 |
Why?
|
Behavior | 1 | 2005 | 85 | 0.060 |
Why?
|
Length of Stay | 3 | 2014 | 733 | 0.060 |
Why?
|
Escherichia coli Infections | 1 | 2005 | 35 | 0.060 |
Why?
|
Iodine Radioisotopes | 1 | 2005 | 134 | 0.060 |
Why?
|
Models, Immunological | 1 | 2004 | 81 | 0.060 |
Why?
|
Glossitis, Benign Migratory | 1 | 2023 | 2 | 0.060 |
Why?
|
Bacteria, Anaerobic | 1 | 2003 | 3 | 0.060 |
Why?
|
Glossitis | 1 | 2023 | 3 | 0.060 |
Why?
|
Tongue Diseases | 1 | 2023 | 10 | 0.060 |
Why?
|
In Situ Hybridization | 2 | 2015 | 313 | 0.060 |
Why?
|
Vinblastine | 1 | 2004 | 108 | 0.060 |
Why?
|
Histone Demethylases | 1 | 2023 | 32 | 0.060 |
Why?
|
Radioimmunotherapy | 1 | 2003 | 27 | 0.060 |
Why?
|
Microtubules | 1 | 2004 | 123 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2007 | 479 | 0.060 |
Why?
|
Severity of Illness Index | 2 | 2021 | 1837 | 0.060 |
Why?
|
Body Temperature | 1 | 2003 | 124 | 0.050 |
Why?
|
Fluid Therapy | 1 | 2003 | 51 | 0.050 |
Why?
|
Pharynx | 1 | 2023 | 45 | 0.050 |
Why?
|
Adenoidectomy | 1 | 2023 | 23 | 0.050 |
Why?
|
Blood Loss, Surgical | 1 | 2003 | 115 | 0.050 |
Why?
|
Neoplasm Grading | 2 | 2016 | 372 | 0.050 |
Why?
|
Intraoperative Care | 1 | 2003 | 84 | 0.050 |
Why?
|
Hot Temperature | 1 | 2003 | 208 | 0.050 |
Why?
|
Brachytherapy | 1 | 2003 | 121 | 0.050 |
Why?
|
Endothelium, Vascular | 1 | 2004 | 433 | 0.050 |
Why?
|
Clostridium Infections | 1 | 2004 | 124 | 0.050 |
Why?
|
Recurrent Laryngeal Nerve | 1 | 2022 | 11 | 0.050 |
Why?
|
Ipilimumab | 1 | 2022 | 61 | 0.050 |
Why?
|
Hydroxyurea | 1 | 2022 | 239 | 0.050 |
Why?
|
Polymerase Chain Reaction | 2 | 2015 | 922 | 0.050 |
Why?
|
Colorectal Neoplasms | 2 | 2007 | 981 | 0.050 |
Why?
|
Amyloid Precursor Protein Secretases | 1 | 2022 | 93 | 0.050 |
Why?
|
Parathyroid Glands | 1 | 2022 | 74 | 0.050 |
Why?
|
Albumins | 1 | 2022 | 129 | 0.050 |
Why?
|
Pyridones | 1 | 2022 | 56 | 0.050 |
Why?
|
Apoptosis | 2 | 2005 | 1717 | 0.050 |
Why?
|
Neovascularization, Pathologic | 1 | 2004 | 364 | 0.050 |
Why?
|
Maximum Tolerated Dose | 1 | 2022 | 272 | 0.050 |
Why?
|
Lip | 1 | 2021 | 16 | 0.050 |
Why?
|
Imidazoles | 1 | 2022 | 148 | 0.050 |
Why?
|
Caenorhabditis elegans | 1 | 2023 | 230 | 0.050 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2021 | 39 | 0.050 |
Why?
|
Models, Animal | 1 | 2022 | 276 | 0.050 |
Why?
|
Logistic Models | 2 | 2016 | 1213 | 0.050 |
Why?
|
Tobacco Use | 1 | 2020 | 27 | 0.050 |
Why?
|
Viral Load | 1 | 2021 | 145 | 0.050 |
Why?
|
Fluorouracil | 1 | 2022 | 561 | 0.050 |
Why?
|
Disease Progression | 2 | 2015 | 1488 | 0.050 |
Why?
|
B7-H1 Antigen | 1 | 2022 | 274 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2020 | 29 | 0.040 |
Why?
|
Hospitals | 1 | 2023 | 299 | 0.040 |
Why?
|
RNA, Viral | 1 | 2021 | 315 | 0.040 |
Why?
|
Cell Line | 4 | 2005 | 2495 | 0.040 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2021 | 282 | 0.040 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 131 | 0.040 |
Why?
|
Medicare | 1 | 2023 | 424 | 0.040 |
Why?
|
Surgical Oncology | 1 | 2020 | 27 | 0.040 |
Why?
|
Efficiency, Organizational | 1 | 2020 | 59 | 0.040 |
Why?
|
Age of Onset | 1 | 2020 | 312 | 0.040 |
Why?
|
India | 1 | 2020 | 123 | 0.040 |
Why?
|
Body Mass Index | 1 | 2003 | 771 | 0.040 |
Why?
|
Genetic Heterogeneity | 1 | 2019 | 63 | 0.040 |
Why?
|
Deglutition | 1 | 2020 | 76 | 0.040 |
Why?
|
Prevalence | 1 | 2023 | 1242 | 0.040 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2019 | 12 | 0.040 |
Why?
|
RNA-Binding Proteins | 2 | 2012 | 258 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase 7 | 1 | 2019 | 22 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2022 | 780 | 0.040 |
Why?
|
Antibodies, Monoclonal | 2 | 2022 | 1402 | 0.040 |
Why?
|
Genes, myc | 1 | 2019 | 39 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 2015 | 1798 | 0.040 |
Why?
|
Enzyme Inhibitors | 1 | 2022 | 645 | 0.040 |
Why?
|
Triage | 1 | 2020 | 111 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 887 | 0.040 |
Why?
|
Aniline Compounds | 1 | 2019 | 58 | 0.040 |
Why?
|
Neural Stem Cells | 1 | 2019 | 58 | 0.040 |
Why?
|
Aging | 1 | 2023 | 716 | 0.040 |
Why?
|
Mice, SCID | 1 | 2019 | 261 | 0.040 |
Why?
|
Lysine | 1 | 2019 | 150 | 0.040 |
Why?
|
Hypoxia | 1 | 2003 | 650 | 0.040 |
Why?
|
Databases, Genetic | 1 | 2019 | 263 | 0.040 |
Why?
|
Medical History Taking | 1 | 2018 | 82 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2004 | 1215 | 0.040 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2018 | 103 | 0.040 |
Why?
|
American Dental Association | 1 | 2017 | 9 | 0.040 |
Why?
|
Evidence-Based Dentistry | 1 | 2017 | 10 | 0.040 |
Why?
|
S-Nitrosoglutathione | 2 | 2009 | 10 | 0.040 |
Why?
|
Disease Management | 1 | 2020 | 329 | 0.040 |
Why?
|
Nitric Oxide Synthase Type I | 2 | 2009 | 22 | 0.040 |
Why?
|
Mouth | 1 | 2017 | 48 | 0.040 |
Why?
|
Two-Hybrid System Techniques | 2 | 2009 | 56 | 0.040 |
Why?
|
N-Methylaspartate | 2 | 2009 | 51 | 0.040 |
Why?
|
Mice, Inbred C57BL | 4 | 2005 | 3211 | 0.040 |
Why?
|
Electromyography | 1 | 2018 | 193 | 0.040 |
Why?
|
Indoles | 1 | 2019 | 312 | 0.040 |
Why?
|
Diagnostic Tests, Routine | 1 | 2017 | 64 | 0.040 |
Why?
|
Histones | 1 | 2019 | 329 | 0.040 |
Why?
|
Germ Cells | 1 | 2017 | 130 | 0.040 |
Why?
|
Exanthema | 1 | 2016 | 39 | 0.030 |
Why?
|
Cetuximab | 1 | 2016 | 117 | 0.030 |
Why?
|
Neutropenia | 1 | 2016 | 216 | 0.030 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2016 | 18 | 0.030 |
Why?
|
Amines | 1 | 2016 | 28 | 0.030 |
Why?
|
Gastroscopy | 1 | 2016 | 25 | 0.030 |
Why?
|
Chemoradiotherapy, Adjuvant | 1 | 2016 | 35 | 0.030 |
Why?
|
Maryland | 1 | 2015 | 42 | 0.030 |
Why?
|
Adenocarcinoma in Situ | 1 | 2015 | 4 | 0.030 |
Why?
|
Protein Transport | 2 | 2009 | 421 | 0.030 |
Why?
|
Surgical Wound Dehiscence | 1 | 2015 | 37 | 0.030 |
Why?
|
Cytodiagnosis | 1 | 2015 | 46 | 0.030 |
Why?
|
Transfection | 2 | 2009 | 911 | 0.030 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2016 | 85 | 0.030 |
Why?
|
Finite Element Analysis | 1 | 2015 | 78 | 0.030 |
Why?
|
Interprofessional Relations | 1 | 2016 | 122 | 0.030 |
Why?
|
Denmark | 1 | 2015 | 17 | 0.030 |
Why?
|
Analgesics, Opioid | 1 | 2020 | 442 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2015 | 83 | 0.030 |
Why?
|
Tracheostomy | 1 | 2015 | 45 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2016 | 354 | 0.030 |
Why?
|
Reference Values | 1 | 2016 | 661 | 0.030 |
Why?
|
Gastrostomy | 1 | 2016 | 69 | 0.030 |
Why?
|
Chicago | 1 | 2020 | 1424 | 0.030 |
Why?
|
Clone Cells | 1 | 2015 | 214 | 0.030 |
Why?
|
Hyperplasia | 1 | 2015 | 152 | 0.030 |
Why?
|
Multimodal Imaging | 1 | 2016 | 111 | 0.030 |
Why?
|
Tadalafil | 1 | 2015 | 1 | 0.030 |
Why?
|
Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2015 | 7 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2016 | 177 | 0.030 |
Why?
|
Mobile Applications | 1 | 2016 | 68 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 895 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2016 | 142 | 0.030 |
Why?
|
Disease Models, Animal | 3 | 2009 | 2363 | 0.030 |
Why?
|
Demography | 1 | 2015 | 181 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 374 | 0.030 |
Why?
|
Analgesics | 1 | 2016 | 119 | 0.030 |
Why?
|
Remission Induction | 1 | 2016 | 740 | 0.030 |
Why?
|
Stress, Mechanical | 1 | 2015 | 253 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2015 | 306 | 0.030 |
Why?
|
PAX5 Transcription Factor | 1 | 2014 | 33 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2016 | 901 | 0.030 |
Why?
|
Paired Box Transcription Factors | 1 | 2014 | 52 | 0.030 |
Why?
|
Precancerous Conditions | 1 | 2015 | 200 | 0.030 |
Why?
|
Quality of Life | 1 | 2022 | 1665 | 0.030 |
Why?
|
Patient Care Team | 1 | 2016 | 283 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2013 | 96 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2015 | 181 | 0.030 |
Why?
|
Mucous Membrane | 1 | 2013 | 83 | 0.030 |
Why?
|
CpG Islands | 1 | 2014 | 157 | 0.030 |
Why?
|
Surgical Wound Infection | 1 | 2015 | 201 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2016 | 3444 | 0.030 |
Why?
|
Protein Binding | 2 | 2009 | 1487 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2019 | 2753 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2019 | 1650 | 0.030 |
Why?
|
Microscopy, Fluorescence | 2 | 2005 | 428 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2017 | 2014 | 0.030 |
Why?
|
Mice, Nude | 2 | 2005 | 814 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 1 | 2015 | 860 | 0.030 |
Why?
|
Transcriptional Activation | 1 | 2013 | 292 | 0.030 |
Why?
|
X-linked Nuclear Protein | 1 | 2012 | 9 | 0.030 |
Why?
|
Mice, Knockout | 2 | 2009 | 1990 | 0.030 |
Why?
|
Cells, Cultured | 2 | 2009 | 2880 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2013 | 1057 | 0.030 |
Why?
|
Baltimore | 1 | 2011 | 40 | 0.020 |
Why?
|
Practice Patterns, Physicians' | 1 | 2017 | 599 | 0.020 |
Why?
|
Time and Motion Studies | 1 | 2011 | 21 | 0.020 |
Why?
|
Seroma | 1 | 2011 | 7 | 0.020 |
Why?
|
Learning Curve | 1 | 2011 | 19 | 0.020 |
Why?
|
Telomere | 1 | 2012 | 114 | 0.020 |
Why?
|
Vocal Cord Paralysis | 1 | 2011 | 27 | 0.020 |
Why?
|
Loss of Heterozygosity | 1 | 2011 | 86 | 0.020 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2011 | 59 | 0.020 |
Why?
|
Ultrasonography | 1 | 2014 | 711 | 0.020 |
Why?
|
Preoperative Period | 1 | 2011 | 94 | 0.020 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2011 | 100 | 0.020 |
Why?
|
Amino Acid Sequence | 2 | 2005 | 2062 | 0.020 |
Why?
|
Hematoma | 1 | 2011 | 108 | 0.020 |
Why?
|
Registries | 1 | 2015 | 780 | 0.020 |
Why?
|
Postoperative Period | 1 | 2011 | 302 | 0.020 |
Why?
|
Genome, Human | 1 | 2015 | 767 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2005 | 3027 | 0.020 |
Why?
|
Prosthesis Design | 1 | 2011 | 297 | 0.020 |
Why?
|
2',5'-Oligoadenylate Synthetase | 1 | 2009 | 9 | 0.020 |
Why?
|
Excitatory Amino Acid Agonists | 1 | 2009 | 45 | 0.020 |
Why?
|
Binding, Competitive | 1 | 2009 | 146 | 0.020 |
Why?
|
Molecular Weight | 1 | 2009 | 331 | 0.020 |
Why?
|
Embryo, Mammalian | 1 | 2009 | 221 | 0.020 |
Why?
|
Green Fluorescent Proteins | 1 | 2009 | 309 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2015 | 1224 | 0.020 |
Why?
|
Thyroglobulin | 1 | 2007 | 59 | 0.020 |
Why?
|
Visual Fields | 1 | 2008 | 98 | 0.020 |
Why?
|
Comorbidity | 1 | 2011 | 948 | 0.020 |
Why?
|
Magnetics | 1 | 2007 | 41 | 0.020 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2007 | 40 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2009 | 557 | 0.020 |
Why?
|
Ultrasonography, Interventional | 1 | 2007 | 123 | 0.020 |
Why?
|
Curriculum | 1 | 2011 | 567 | 0.020 |
Why?
|
Visual Acuity | 1 | 2008 | 198 | 0.020 |
Why?
|
Substrate Specificity | 1 | 2007 | 352 | 0.020 |
Why?
|
Infant | 1 | 2013 | 3149 | 0.020 |
Why?
|
Fluorescent Dyes | 1 | 2007 | 243 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2009 | 681 | 0.020 |
Why?
|
Antibodies | 1 | 2007 | 353 | 0.020 |
Why?
|
Densitometry | 1 | 2005 | 29 | 0.020 |
Why?
|
Escape Reaction | 1 | 2005 | 12 | 0.020 |
Why?
|
Huntingtin Protein | 1 | 2005 | 13 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2007 | 691 | 0.020 |
Why?
|
Electron Transport | 1 | 2005 | 74 | 0.020 |
Why?
|
Retinal Degeneration | 1 | 2005 | 29 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2005 | 240 | 0.020 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2005 | 88 | 0.020 |
Why?
|
Blotting, Northern | 1 | 2005 | 258 | 0.020 |
Why?
|
Nitric Oxide Synthase | 1 | 2005 | 126 | 0.020 |
Why?
|
Chromatography, Affinity | 1 | 2004 | 81 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2005 | 275 | 0.020 |
Why?
|
Plasmids | 1 | 2005 | 291 | 0.020 |
Why?
|
Ubiquitin | 1 | 2005 | 96 | 0.020 |
Why?
|
Cysteine | 1 | 2005 | 136 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 2005 | 221 | 0.010 |
Why?
|
Cytoplasm | 1 | 2005 | 284 | 0.010 |
Why?
|
Spores | 1 | 2004 | 2 | 0.010 |
Why?
|
Cesium Radioisotopes | 1 | 2003 | 12 | 0.010 |
Why?
|
Gene Deletion | 1 | 2005 | 342 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2004 | 274 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 2005 | 293 | 0.010 |
Why?
|
Nitric Oxide | 1 | 2005 | 279 | 0.010 |
Why?
|
Regional Blood Flow | 1 | 2004 | 198 | 0.010 |
Why?
|
Necrosis | 1 | 2004 | 209 | 0.010 |
Why?
|
Alternative Splicing | 1 | 2004 | 210 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 2003 | 510 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 2003 | 397 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2005 | 599 | 0.010 |
Why?
|
Cell Survival | 1 | 2005 | 982 | 0.010 |
Why?
|
Oligopeptides | 1 | 2004 | 188 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2004 | 370 | 0.010 |
Why?
|
Behavior, Animal | 1 | 2005 | 378 | 0.010 |
Why?
|
Macrophages | 1 | 2005 | 571 | 0.010 |
Why?
|
Escherichia coli | 1 | 2005 | 605 | 0.010 |
Why?
|
Mitochondria | 1 | 2005 | 553 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2005 | 1574 | 0.010 |
Why?
|
Drosophila | 1 | 2005 | 521 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2005 | 1157 | 0.010 |
Why?
|
Brain | 1 | 2009 | 2281 | 0.010 |
Why?
|
Rats | 1 | 2005 | 4041 | 0.010 |
Why?
|